Windtree Therapeutics (WINT) AI Stock Analysis

• Market Cap: $3.00M
• Dividend Yield: N/A
• Average Volume (3M): 254.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.61
• Revenue Growth: N/A
• EPS Growth: 97.84%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -4.63
• Shares Outstanding: 3,661,289
• 10 Day Avg. Volume: 141,834
• 30 Day Avg. Volume: 254,634
• PEG Ratio: <0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.20
• Enterprise Value/Market Cap: 1.09
• Enterprise Value/Revenue: 36.26
• Enterprise Value/Gross Profit: 155.39
• Enterprise Value/Ebitda: -0.10
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 28 Underperform
• Price Target: ―

Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Recent corporate events provide a minor positive outlook, but overall, the stock presents considerable risks with limited upside potential without a substantial change in financial performance or market conditions.

Windtree Therapeutics Business Overview & Revenue Model

Company Description

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.

How the Company Makes Money

Windtree Therapeutics generates revenue primarily through the development and commercialization of its proprietary therapeutic products, including licensing agreements and collaboration partnerships. The company may receive milestone payments, royalties, and other financial support from partnerships with larger pharmaceutical companies interested in their novel therapies. Additionally, Windtree may secure funding through government grants or research and development contracts aimed at advancing its clinical trials and product development initiatives. The company's financial success is closely tied to the progress and approval of its drug candidates in regulatory pathways and the subsequent commercialization efforts.

Windtree Therapeutics Financial Statement Overview

Summary

Windtree Therapeutics is in a challenging financial situation, with no revenue generation and significant net losses impacting its financial health. The balance sheet shows a leveraged position with declining equity, while cash flows indicate reliance on external financing. The lack of revenue severely limits potential growth opportunities and stability in the biotechnology sector.

Income Statement

The company has reported zero revenue over the years, leading to negative profitability metrics. Consistent net losses highlight significant operational challenges, with no revenue growth potential in sight. The lack of revenue and high net losses severely impact the overall financial health.

Balance Sheet

The company shows a weak financial position with declining stockholders' equity over the years. The debt-to-equity ratio is relatively high, indicating significant leverage, though the current debt levels are not excessively high. The company needs to improve its equity base to stabilize its balance sheet.

Cash Flow

The cash flow position is strained with consistently negative operating and free cash flows, indicating insufficient cash generation from operations. Financing activities have been a key source of cash, highlighting reliance on external funding. The company faces challenges in maintaining cash reserves without revenue generation.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
45.00K	0.00	0.00	0.00	0.00	0.00
	Gross Profit
21.00K	0.00	-82.00K	-1.06M	-869.00K	-638.00K
	EBIT
-21.73M	-25.02M	-17.54M	-41.33M	-77.28M	-30.32M
	EBITDA
-11.75M	0.00	-20.16M	-39.46M	-76.64M	-31.80M
	Net Income Common Stockholders
-20.75M	-5.49M	-20.29M	-39.21M	-67.64M	-30.28M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.17M	1.78M	4.32M	6.17M	22.35M	16.93M
	Total Assets
26.77M	27.88M	32.41M	37.95M	74.79M	112.89M
	Total Debt
1.41M	1.82M	16.83M	2.28M	2.89M	3.78M
	Net Debt
239.00K	43.00K	12.51M	-3.89M	-19.45M	-13.15M
	Total Liabilities
15.44M	17.88M	29.02M	27.94M	32.91M	43.33M
	Stockholders Equity
1.04M	10.00M	3.39M	10.01M	41.88M	69.55M
Cash Flow		Free Cash Flow
-14.87M	-15.41M	-13.45M	-19.46M	-23.94M	-25.61M
	Operating Cash Flow
-14.86M	-15.40M	-13.44M	-19.45M	-23.66M	-25.32M
	Investing Cash Flow
-12.00K	-12.00K	-15.00K	197.00K	-279.00K	-291.00K
	Financing Cash Flow
13.50M	12.73M	11.60M	3.08M	29.36M	19.96M

Windtree Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.79
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WINT, the sentiment is Negative. The current price of 0.79 is below the 20-day moving average (MA) of 0.95, below the 50-day MA of 1.27, and below the 200-day MA of 80.83, indicating a bearish trend. The MACD of -0.19 indicates Negative momentum. The RSI at 29.52 is Positive, neither overbought nor oversold. The STOCH value of 24.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WINT.

Windtree Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.24B	3.07	-43.58%	2.80%	16.87%	-0.11%
SONN	48 Neutral	$4.15M	―	-714.96%	―	978.39%	69.65%
TOVX	45 Neutral	$3.57M	―	-100.01%	―	―	6.87%
TCRT	45 Neutral	$4.42M	―	-139.06%	―	80.00%	86.70%
XBIO	43 Neutral	$4.69M	―	-53.16%	―	-1.56%	5.01%
OGEN	29 Underperform	$4.27M	―	-748.05%	―	-100.00%	76.55%
WINT	28 Underperform	$3.00M	―	-120.01%	―	―	97.84%

Windtree Therapeutics Corporate Events

Windtree Therapeutics Raises $2.5M in Private Placement

On April 19, 2025, Windtree Therapeutics, through its subsidiary WINT Real Estate, LLC, entered into an Assignment and Conditional Assumption Agreement with Way Maker Growth Fund, LLC to acquire a multifamily residential property in Houston, Texas. This strategic move is part of Windtree’s plan to generate consistent rental revenue while continuing to develop its therapeutic pipeline. The acquisition is expected to be funded primarily through non-recourse secured mortgage financing, supplemented by proceeds from the issuance of preferred stock. Additionally, on April 29, 2025, Windtree completed a Securities Purchase Agreement for a private placement of Series D Convertible Preferred Stock, raising approximately $2.5 million. This financial maneuver is aimed at supporting the company’s strategy to diversify revenue sources and stabilize its operations, reducing reliance on potentially dilutive capital.

Spark’s Take on WINT Stock

According to Spark, TipRanks’ AI Analyst, WINT is a Underperform.

Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Overall, the stock presents considerable risks, with limited upside potential without a substantial change in financial performance or market conditions.

To see Spark’s full report on WINT stock, click here.

Windtree Therapeutics Announces Reverse Stock Split Approval

Windtree Therapeutics, Inc. announced a 1-for-50 reverse stock split of its common stock, effective February 20, 2025, with the aim of meeting Nasdaq’s $1.00 minimum bid price requirement. This strategic move, approved by stockholders on February 3, 2025, is expected to consolidate shares and increase the stock price, impacting the company’s trading on the Nasdaq Capital Market.